Volume 13, Number 1—January 2007
Model for Assessing Human Papillomavirus Vaccination Strategies
|18-y-old women plus 18- to 24-y-old female catch-up||73,553,847||2,699,192||1,858|
|15-y-old female adolescents plus 15- to 24-y-old female catch-up||73,895,046||2,699,214||Weakly dominated|
|12-y-old girls plus 12- to 24-y-old female catch-up||74,815,667||2,699,343||8,357|
|18-y-old women and men plus 18- to 24-y-old female and male catch-up||77,535,383||2,699,385||Weakly dominated|
|15-y-old female and male adolescents plus 15- to 24-y-old female and male catch-up||78,455,750||2,699,404||Weakly dominated|
|12-y-old female and male adolescents plus 12- to 24-y-old female and male catch-up program||81,761,210||2,699,506||42,697|
*Assumes cost of vaccination series is US $360, duration of protection is lifelong, and coverage rate of 50% among age 15- to 24-y-olds. HPV, human papillomavirus; QALY, quality-adjusted life years.
†Compared with the preceding nondominated strategy. Strategy A is dominated if there is another strategy, B, that is more effective and less costly than strategy A. A strategy is weakly dominated if there is another more effective program that has a incremental cost-effectiveness ratio.
- Page created: June 28, 2010
- Page last updated: June 28, 2010
- Page last reviewed: June 28, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)